Shares of Shilpa Medicare Ltd. gained 3% in intraday trade on Friday, February 13, following the company's announcement of a significant international partnership. According to reports from CNBC TV18, the stock jumped as much as 3.04% to hit an intraday high of ₹333.15 apiece on the BSE, though it later pared some gains to trade at ₹333.1 apiece, up 3.03% at 1:20 pm. As per the latest market data, Shilpa Medicare share price stands at ₹326.80 per share on the BSE as of 13 February 2026 at 03:30 PM IST, reflecting routine market activity as investors assessed the long-term implications of the partnership.
The Karnataka-based pharmaceutical company has entered into a binding development and supply agreement with Switzerland-based NXI Therapeutics AG for a New Chemical Entity (NCE). As reported by Shilpa Medicare press release, the arrangement falls under Regulation 30 of the SEBI Listing Regulations and covers development activities through to potential commercial supply. Under the collaboration, Shilpa Medicare will provide comprehensive CMC development, process scale-up, GMP clinical supply and commercial manufacturing support. The scope includes long-term commercial manufacturing across agreed territories, subject to regulatory progression, with no related party involvement and no share exchange ratio applicable.
According to the company's press release, under the terms of the agreement, Shilpa Group will provide comprehensive CMC development, process scale-up, GMP clinical supply and commercial manufacturing support. The collaboration spans early development through commercialisation, positioning Shilpa as a lifecycle partner for the programme. The partnership positions Shilpa Medicare as a lifecycle development and manufacturing partner for the programme, supporting early-stage development, including first-in-human clinical studies, followed by scale-up and regulated manufacturing support. The agreement provides a structured framework for milestone-linked development and commercial engagement.
As reported by Shilpa Medicare, the autoimmune and immune-modulation segment represents one of the fastest-growing therapeutic categories globally, driven by increasing prevalence and demand for targeted immunotherapies. The company stated that by securing this mandate at an early stage, the company enhances its participation in high-value, innovation-driven pipelines with scalable commercial potential. The collaboration strengthens Shilpa's contract development and manufacturing portfolio and continues to expand its engagement with international biotechnology firms seeking integrated research and GMP manufacturing capabilities.
This marks the third major international development and manufacturing contract for Shilpa Group. In its Q3FY26 results released last week, Shilpa Medicare reported a 40.3% year-on-year rise in profit after tax at ₹44.6 crore from ₹32 crore in the year-ago quarter. Revenue for the December quarter increased 28% YoY to ₹409 crore from ₹319.3 crore a year ago. The autoimmune therapy segment continues to attract research investment due to rising diagnosis rates and demand for targeted therapies, with the collaboration strengthening Shilpa's participation in innovation-led development programmes.
